Company planning a demerger to unlock shareholders value ,as it is the only pharma company with lowest PE which is 10 , though company enjoys good revenue
Also keep an eye on 20 EMA
Can be bought for short time period
免责声明
这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在
使用条款阅读更多信息。